Adlai Nortye Ltd V.ANL.H

Primary Symbol: ANL

Healthcare Biotechnology

Adlai Nortye Ltd is a Cayman Island-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of cancer therapies. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.

NDAQ:ANL - Post by User

Adlai Nortye Ltd > VALUATION

<< Previous

Bullboard Posts

Next >>

Post by Rick2012on Feb 12, 2018 1:22pm

269 Views

Post# 27545539

VALUATION

on ***2 million tonnes per year*** production.

If ANL could make $30 operating profit per tonne for years 1-10, $35 from years 11-20, and $40 from years 21-30, the NPV on the cash flows with 8% discount rate and initial capex of $700 million (hope Nova Scotia government can kick in $100 million), I arrive at a $35 million NPV.

On 25 million shares outstanding that’s $1.40 per share.
The stock is at 3 cents...wow!!!

<< Previous

Bullboard Posts

Next >>

TELUS adds 347K customers in Q3